MobiHealth News October 22, 2021
The deal is expected to close by the end of 2021.
Consumer genetics company 23andMe announced Friday it has signed a definitive agreement to acquire telehealth and online prescription platform Lemonaid Health for $400 million.
The price tag, subject to downward adjustments, will be made up of 25% in cash and 75% in stock. The companies expect the acquisition to close by the end of the year.
“We believe that by combining Lemonaid Health’s telemedicine platform, including its online team of medical professionals and its pharmacy services, with our consumer business, we are taking an important step in transforming the traditional primary care experience and making personalized healthcare a reality,” Anne Wojcicki, CEO and cofounder of 23andMe, said in...
Today's Sponsors
Today's Sponsor